The thesis
Momentum SMA20 Rider is an unapologetic trend-follower. It ranks its 24-name large-cap universe by distance above the SMA50, buys the leaders whose price is still holding above the SMA20, and rides them until one of two things breaks the story: RSI14 pushing past 75 (overbought) or a close back below the SMA20 (trend structure gone). When the book is full, capital rotates out of the weakest holdings into higher-ranked names. It is a clean, rules-based expression of "buy strength, cut when strength fades."
Validation: the case for
The strategy passed its four-fold walk-forward gate, and the numbers behind that pass are the most encouraging part of the story. Three of four folds were positive, and the deflated metrics hold up: a Probabilistic Sharpe Ratio of 0.986 and a Deflated Sharpe Ratio of 0.583 across 24 trials suggest the edge is not purely an artifact of selection. The most recent out-of-sample fold (2025-05-17 to 2026-08-05) is the standout — 43.48% return, a 2.18 Sharpe, and only a 5.38% max drawdown. Over the full backtest the system compounded to $18,100 from a nominal start, an 81% total return and 12.89% CAGR across 1,233 days.
Validation: the case for caution
Balance matters here. The win rate is just 37.13% across 1,427 trades — this is a strategy that survives on a fat right tail, not on being right often. Turnover is extreme at roughly 26,972%, so frictions and slippage in live markets could bite far harder than a backtest with flat FX costs and modest fees implies. Fold performance is also uneven: Fold 3 (2024-02-28 to 2025-05-17) essentially flatlined at -0.28% while carrying the deepest drawdown of the study at 23.02%, and Fold 1 managed only 4.77%. The full-period max drawdown of 20.91% is real risk that a live allocator has to be willing to sit through.
Recent activity
The strategy went live on 2026-08-06, deployed with $10,000 and clearing review at a low risk score of 0.3 (the reviewer flagged only minor robustness gaps around missing-budget and null-momentum handling). Its opening run executed five buys — notably a financials tilt into JPM, BAC, V, and MA, plus a healthcare position in ABBV — leaving $626.50 in cash.
Since then it has been quiet. The scheduled runs on 2026-08-06, 08-07, and 08-10 each executed zero trades, which is consistent with a hold-the-trend design once positioned. Total account value has drifted between $9,832 and $9,884, sitting at $9,839.71 as of the latest run — modestly below the $10,000 start.
Read-through
Momentum SMA20 Rider is a credible, well-validated trend system whose recent out-of-sample stretch is genuinely strong. But its low hit rate, punishing turnover, and one dead fold mean it needs a patient owner and real attention to trading costs. The first live week — five entries, then stillness, and a slight dip below par — is too short to judge. The validation earns it a seat; the live tape has yet to say anything at all.